** Shares of Abbott India Ltd ABOT.NS climb 4.4% to 29,030 rupees
** JP Morgan ("overweight") lifts PT on stock to 34,000 rupees from 31,500 rupees, a Street-high, as per data compiled by LSEG
** Drugmaker's Q3 consol net profit jumped 16% Y/Y on Wednesday, stock jumped ~4%
** ABOT benefitted from its unique strategy of tailoring product launches to fit local markets, says JPM
** Adds, strong demand for Rybelsus, oral version of Novo Nordisk's NOVOb.CO weight-loss drug, boosted sales
** Avg rating of four analysts on ABOT at "strong buy"; median PT is 31,850 rupees - LSEG data
** Stock gained ~30% in 2024
(Reporting by Nandan Mandayam in Bengaluru)
((Nandan.Mandayam@thomsonreuters.com; Mobile: +91 9591011727;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.